Drug Detail

Drug Name inotuzumab ozogamicin
Trade Name Besponsa
Synonyms CMC-544|InO
Drug Descriptions

Besponsa (inotuzumab ozogamicin) consists of calecheamicin covalently linked to anti-CD22 antibody, which delivers calecheamicin into CD22-positive cells, leading to DNA damage and apoptosis (PMID: 24389139). Besponsa (inotuzumab ozogamicin) is FDA approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (FDA.gov).

DrugClasses

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Therapy Description
Fludarabine + inotuzumab ozogamicin + Melphalan + Tacrolimus
inotuzumab ozogamicin + Vincristine sulfate liposome
Bendamustine + Fludarabine + inotuzumab ozogamicin Besponsa (inotuzumab ozogamicin) consists of calecheamicin covalently linked to anti-CD22 antibody, which delivers calecheamicin into CD22-positive cells, leading to DNA damage and apoptosis (PMID: 24389139). Besponsa (inotuzumab ozogamicin) is FDA approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (FDA.gov).
inotuzumab ozogamicin
Bosutinib + inotuzumab ozogamicin
Cyclophosphamide + inotuzumab ozogamicin + Prednisone + Rituximab + Vincristine
Cytarabine + inotuzumab ozogamicin + Methotrexate
Blinatumomab + inotuzumab ozogamicin Blincyto (blinatumomab) is a bispecific antibody that binds both CD19 on B-cells and the CD3 complex on T-cells, therefore facilitates T-cell mediated killing of CD19-expressing tumor cells (PMID: 26337639). Blincyto (blinatumomab) is FDA approved for the treatment of B-cell precursor acute lymphoblastic leukemia in adult and children negative for BCR-ABL1 (FDA.gov).
Bendamustine + Fludarabine + inotuzumab ozogamicin + Tacrolimus
Cyclophosphamide + Cytarabine + inotuzumab ozogamicin + Methotrexate + Vincristine